Intezyne is continually evaluating potential partnering opportunities for the development of its products. We are actively collaborating with other biopharmaceutical companies to develop new product candidates, as well as working with respected academic and research institutions to further our understanding.
Are you interested in partnering with Intezyne?
For more information on partnering, please contact us.
Available Assets for Partnership
IT-141
IT-141 leverages Intezyne's proprietary nanoparticle technology (IVECT) to deliver SN-38, an extremely potent topoisomerase-1 (TOP-1) inhibitor, directly to tumors.
IT-147
IT-147 leverages Intezyne’s proprietary nanoparticle technology (IVECT) to deliver epothilone, a potent anti-microtubule agent, directly to tumors.
Other Programs
Intezyne’s proprietary polymer technologies can improve the delivery of a wide variety of hydrophobic molecules, including molecularly targeted therapeutics, immuno-oncology small molecule agonists and antagonists, and cytotoxic chemotherapeutics.
DEVELOPMENT PARTNERSHIPS
IT-139 / BOLD-100
Novel anti-resistance agent for the treatment of solid tumors
Academic PartnerSHIPS
H. Lee Moffitt Cancer Center
Drug Discovery: IVECT formulations for novel proapoptotic agent
Massey Cancer Center
Drug Discovery: IVECT formulations for novel kinase inhibitor
Florida International University, Biomolecular Sciences Institute
IT-141 (IVECT-SN38) novel TOP-1 inhibitor
Industry PartnerSHIPS
Intezyne is collaborating with scientists at the Nanotechnology Characterization Laboratory on development of advanced analytical assays related to nanoparticle drug release profiles.